Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung cancers are non-small cell lung cancers, in which tumor cells are larger and ...

Cancer spreading to the lungs is a common and concerning development in advanced stages of the disease. More than half of people with advanced cancer in other parts of their body eventually develop ...

“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

Rare inherited genetic variants significantly increase familial lung cancer risk, offering new targets for early detection.

Researchers of the University of Barcelona and the August Pi y Sunyer Biomedical Research Institute (IDIBAPS) have shown that the IGFBP3 protein plays a relevant role in human lung development. The ...

Patritumab deruxtecan's BLA withdrawal was due to HERTHENA-Lung02 trial's unsatisfactory overall survival results, despite progression-free survival significance. The HERTHENA-Lung02 trial compared ...

Blood clots form in response to signals from the lungs of cancer patients -- not from other organ sites, as previously thought -- according to a preclinical study. Clots are the second-leading cause ...

Susan Wojcicki, the late CEO of YouTube, had a message for the world just weeks before she passed. “Although lung cancer overall is decreasing because of declines in tobacco use, lung cancer among ...

Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...